Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
European Radiology

18-12-2024 | Computed Tomography | Commentary

PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass

Authors: Matteo Bauckneht, Riccardo Laudicella, Francesco Lanfranchi, Chiara Ciccarese

Published in: European Radiology

Login to get access

Excerpt

Between one-quarter and one-half of all prostate cancer (PCa) patients who undergo radical prostatectomy (RP) or curative radiotherapy (RT) experience a rising prostate-specific antigen (PSA) level. Biochemical recurrence (BCR) after treatment has long been defined as a PSA level of ≥ 0.2 ng/mL and rising following RP or an increase of ≥ 2 ng/mL above the post-RT nadir. However, the concept of BCR is evolving with the latest European Association of Urology (EAU) guidelines questioning 0.2 ng/mL as the optimum cut-off after RP [1]. …
Literature
1.
Tilki D, van den Bergh RCN, Briers E et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol 86:164–182CrossRefPubMed
2.
Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208–1216CrossRefPubMed
3.
Morris MJ, Rowe SP, Gorin MA et al (2021) Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res 27:3674–3682CrossRefPubMedPubMedCentral
4.
Pienta KJ, Gorin MA, Rowe SP et al (2021) A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol 206:52–61CrossRefPubMedPubMedCentral
5.
Olivier P, Giraudet AL, Skanjeti A et al (2023) Phase III study of 18F-PSMA-1007 versus 18F-fluorocholine PET/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study. J Nucl Med 64:579–585CrossRefPubMedPubMedCentral
6.
Bukavina L, Luckenbaugh AN, Hofman MS et al (2023) Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer. Eur Urol 83:521–533CrossRefPubMed
7.
Parker CC, Kynaston H, Cook AD et al (2024) Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet 403:2416–2425CrossRefPubMedPubMedCentral
8.
Freedland SJ, de Almeida Luz M, De Giorgi U et al (2023) Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med 389:1453–1465CrossRefPubMed
9.
Armstrong WR, Clark KJ, Smith CP et al (2023) PSMA PET findings in an “EMBARK-like” cohort of patients with high-risk non-metastatic hormone-sensitive prostate cancer: a single center post-hoc retrospective analysis. J Clin Oncol 41:5091–5091CrossRef
10.
Jani AB, Schreibmann E, Goyal S et al (2021) 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet 397:1895–1904CrossRefPubMedPubMedCentral
11.
Gunnlaugsson A, Johannesson V, Wieslander E et al (2022) A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy—the PROPER 1 trial. Clin Transl Radiat Oncol 36:77–82PubMedPubMedCentral
12.
Meijer D, Eppinga WSC, Mohede RM et al (2022) Prostate-specific membrane antigen positron emission tomography/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol 5:146–152CrossRefPubMed
13.
Bauckneht M, Lanfranchi F, Albano D et al (2024) Diverse imaging methods may influence long-term oncologic outcomes in oligorecurrent prostate cancer patients treated with metastasis-directed therapy (the PRECISE-MDT study). J Nucl Med 65:1202–1209CrossRefPubMedPubMedCentral
Metadata
Title
PSMA PET/CT in staging recurrent prostate cancer: a viewfinder, not a compass
Authors
Matteo Bauckneht
Riccardo Laudicella
Francesco Lanfranchi
Chiara Ciccarese
Publication date
18-12-2024
Publisher
Springer Berlin Heidelberg
Published in
European Radiology
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-024-11297-z